title: New intranasal formulations for the treatment of allergic rhinitis.
abstract: Intranasal corticosteroids (INSs) have been effectively used for >40 years for the treatment of seasonal allergic rhinitis (SAR) and perennial AR (PAR). Following the Montreal Protocol, the initial aerosol formulations using chlorofluorocarbon (CFC) propellants were phased out. For the past 20 years, aqueous solutions have been the only available option for INS treatment. In 2012, the U.S. Food and Drug Administration approved two new nonaqueous aerosol AR treatments that use a hydrofluoroalkane (HFA) propellant. In 2012, the first intranasal aqueous combination product was also approved. This article reviews the clinical profiles of HFA beclomethasone dipropionate (BDP) and HFA ciclesonide (CIC) and the aqueous combination intranasal antihistamine (INA)/INS formulation of azelastine hydrochloride/fluticasone propionate (AZE/FP). The medical literature was searched for clinical trials investigating the use of BDP, CIC, and AZE/FP in SAR and PAR. Clinical trials involving aqueous solutions and CFC propellant or HFA propellant delivery were included. Data from prescribing information and published efficacy and safety data were presented as part of the clinical profile for the reviewed agents. AZE/FP has shown efficacy and safety comparable or greater with the current AR treatment options. Although efficacy comparisons of new HFA formulations have not been investigated in head-to-head clinical trials with aqueous formulations, HFA formulations have shown similar efficacy rates. Furthermore, HFA formulations may have some additional benefits, including a preferable sensory profile for some patients. These new formulations will provide additional options for clinicians and patients to better individualize therapy for control of AR.
authors.forename: Eli O
authors.initials: EO
authors.lastname: Meltzer
authors.forename: Greg W
authors.initials: GW
authors.lastname: Bensch
authors.forename: William W
authors.initials: WW
authors.lastname: Storms
mesh_terms: D000281:Administration, Intranasal; D000335:Aerosol Propellants; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D001507:Beclomethasone / Q000008:administration & dosage; D002626:Chemistry, Pharmaceutical; D004338:Drug Combinations; D006801:Humans; D011282:Pregnenediones / Q000008:administration & dosage; D065631:Rhinitis, Allergic / Q000188:drug therapy*
chemical_list: D000335:Aerosol Propellants; D018926:Anti-Allergic Agents; D004338:Drug Combinations; D011282:Pregnenediones; D001507:Beclomethasone; C120481:ciclesonide